Background This study was designed as an opportunistic screening to estimate the prevalence of blood-borne viral infection among drug users in treatment in the rural population and to investigate related risk factors and use of general health services.
Introduction
The drug problem in the United Kingdom is no longer con®ned to cities and urban areas; the nature and extent of illicit drug use and risk behaviours for blood-borne viral infections in rural Britain is increasingly of interest.
Keene et al., 1 in their evaluation of syringe-exchange for HIV prevention in Wales, highlighted some of the dif®culties of service provision in rural areas, notably the widely dispersed population and limited access to specialized services. What geographical variations exist in the distribution of services and access to services in rural populations in comparison with innercity and urban areas remain unclear. Haw and Higgins, 2 in their comparison of HIV infection and injecting risk behaviours in urban and rural Scotland, observed a high level of service contact among rural i.v. drug users and a low prevalence of HIV infection, based on anonymous testing for antibodies in saliva specimens. But does a high level of contact with drug misuse treatment agencies necessarily imply effective use of general medical services?
Much of what we know in the United Kingdom about the prevalence of human immuno-de®ciency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infection among drug users has come largely from urban and inner-city areas from either a combination of anonymous self-completion questionnaires and the results of saliva sampling techniques 3À5 or analysis of blood test results of requests made from widely different treatment populations to virology laboratories for serum antibodies. 6 Health service utilization among injecting drug users has also come under increasing scrutiny, although there is a paucity of data on urban±rural differences. Since Farrell et al. 7 reported in a questionnaire survey of statutory treatment facilities that 64 per cent did not screen for HBV markers and that 71 per cent did not offer hepatitis B vaccination, more recent communications in the literature 8, 9 have drawn attention to the poor service utilization among drug users and resource problems of treatment services in promoting a programme of screening or vaccination, or offering effective follow-up for patients at risk of developing chronic liver disease.
If poverty in rural areas is associated with poor health, as Cox 10 has suggested, we may assume that injecting drug users, largely unemployed and likely to suffer socio-economic deprivation, would be doubly disadvantaged in rural populations, and not only be at increased risk of infection with blood-borne viruses but also have limited access to medical care outside the immediate therapeutic options available within drug treatment services. We report the ®ndings of our study, which involved face-to-face interviews with drug users, in treatment and serological markers of HIV, HBV and HCV in rural south-east England. The aims were twofold: to estimate the prevalence of blood-borne viral infection in the treatment population and to investigate related risk factors and use of general health services.
Patients and methods

Setting
The Substance Misuse Services based at the Princess Royal Hospital, Mid-Sussex NHS Trust, Haywards Heath, serves the whole of the Mid-Downs district of Sussex in south-east England, with a population of 281 535 at the 1991 Census. A rich network of roads and rail transport and the international airport at Gatwick permit ease of travel and mobility in and out of the district for an ambulant drug-using population moving between Croydon and London to the north and Brighton, Hove, Worthing, Hastings and Eastbourne to the south. Services to drug users are provided by one of two substance misuse teams, the community drug team, which offers a comprehensive range of therapeutic options including advice and information, a referral and assessment service, methadone substitution for opiate dependence, provision of counselling for all classes of drugs, in-patient detoxi®cation, and community care assessment for residential rehabilitation.
Recruitment and interviews
Subjects in the study were patients, aged 18 years and over, who were referred for problematic self-reported drug use or were already in treatment; all gave informed consent. Individual patients were recruited into the study following clinical assessment and urine toxicology, after consultation with key workers in the community drug team.
Although none of the patients approached refused to be interviewed, the widely dispersed population in the rural setting, without readily available public transport, made recruitment dif®cult. When contact was made with a patient at one of several care delivery sites, a structured interview was carried out by the research nurse; this took place either at one of the three hospitals out-patient departments at Crawley, Horsham or Haywards Heath or at the patient's home or other venues in the local community. All interviews were face to face and included referral details, socio-demographic information, drug use and related complications, injecting and sexual behaviour, health service utilization, past history of sexually transmitted diseases, blood-borne virus infection and hepatitis B vaccination. All patients considered for methadone prescribing met the DSM-111-R criteria 11 for opiate dependence.
Data collection was conducted in a 12 month period from 1 February 1996 to 31 January 1997. Patients were excluded if they were under 18 years of age or had evidence of mental illness or organic disease, or were pregnant. The study protocol was approved by Mid-Sussex NHS Trust research ethics committee.
Serological tests
Blood specimens provided by patients were centrifuged within hours of collection to separate plasma from red blood cells and the sera obtained stored at À308C, until required for analysis. Serological tests for markers of HIV, HBV and HCV were carried out at two independent laboratories. Preliminary tests were conducted at the Department of Clinical Pathology, Princess Royal Hospital, Haywards Heath, West Sussex; test results were con®rmed with the Public Health Laboratory Service (PHLS) at Colindale in London.
Informed consent and pre-test counselling preceded serological tests for the detection of antibodies to human immunode®ciency virus type 1 and type 2 (HIV-1 and HIV-2), performed on serum samples using the recombigen rapid test (Cambridge Biotech Corporation). 12 Positive test results were con®rmed by the PHLS virus reference division (VRD).
Serum samples were assayed for antibodies to hepatitis B core antigen (anti-HBc) by the IMx CORE enzyme-linked immunosorbent assay (ELISA). 13 Specimens for which positive test results were obtained were screened for hepatitis B surface antigen (HBsAg) using the IMx third-generation microparticle enzyme immunoassay (Abbott Laboratories, Chicago, IL, USA).
14 Serum samples positive for HBsAg were further tested for hepatitis Be antigen (HBeAg) for evidence of high infectivity. Antibodies to hepatitis C were initially detected by Abbott Laboratories IMx HCV microparticle enzyme immunoassay (MEIA). Positive test results were checked with the PHLS VRD for con®rmation, using a recombinant immunoblot assay (RIBA) and two enzyme immunoassays ± Ortho EIA 15 and Sano® EIA. 8 Determination of immunoglobulin concentrations in patients anti-HCV positive, IgG and IgM was carried out selectively using the PHLS in-house procedures.
Con®dentiality was maintained with unique study numbers known only to the principal investigators, to link data from the interviews to the clinical records and laboratory results. Every participant was con®dentially informed of the test results face to face. All HBV and HCV test results were communicated formally to the respective general practitioners (GPs).
Other laboratory investigations
Haematological and biochemical pro®les were measured. Concentrations of serum aspartate aminotransferase and gamma-glutamyl transpeptidase were speci®cally noted for liver function tests.
Data processing and analysis
Quanti®able data were stored in a coded format and transferred to the University of London mainframe computer at King's College Hospital Medical School, London. Detailed notes of a qualitative nature made at interviews were stored on a wordprocessing package. The data were analysed with the SPSSX statistical package. Categorical variables were compared by x 2 test, with Yates correction for continuity, or Fisher's exact test for small cell numbers. Continuous variables were analysed using the non-parametric Mann±Whitney U-test. All p values are two-tailed, and at the 5 per cent level of signi®cance.
Results
Sociodemographic characteristics of the sample
In all, 102 patients (78 male, 24 female, ratio 3:1) with a mean age of 32.13 years (SD 7.55; range 18±49 years) were recruited into the study during the 12 months from 1 February 1996 to 31 January 1997. Twenty-eight (27.5 per cent), 18 (17.6 per cent), 7 (6.9 per cent), 11 (10.8 per cent) and 11 (10.8 per cent) were residents of the local towns: Crawley, Horsham, Haywards Heath, Burgess Hill and East Grinstead, respectively; the remaining 27 (26.4 per cent) came from the surrounding villages. All were white British except ®ve (4.9 per cent) who were white but of non-British origin. Excluding ®ve patients who were in further education or housework, 69 (67.6 per cent) were unemployed; 70 (68.6 per cent) were in treatment at the beginning of the study; and 32 (31.4 per cent) were new referrals.
Drug use HIV, HBV and HCV seroprevalence
The main drug of dependence for which treatment was being sought was heroin, reported in 67 patients (65.7 per cent); added to another 20 patients using physeptone ampoules prescribed from private clinics, methadone tablets, dihydrocodeine and opioid cough suppressants, as the main drug at referral, opiate misuse represented 87 (85.3 per cent) of the sample.
The mean age at onset of illicit drug use for the entire sample was 15.33 years (SD 3.36); the mean age at onset of opioid use was 19.47 years (SD 4.15), the mean duration of opioid use being 10.00 years (SD 11.03).
Eight patients refused to provide blood specimen for laboratory investigations; in another ®ve patients venepuncture was unsuccessful. Blood specimens were obtained from 89 (88.1 per cent) of the sample; 27 (26.5 per cent) consented to HIV antibody test and of these one patient was seropositive, representing 3.7 per cent of those tested.
Eighteen (20.4 per cent) of the 88 patients tested for antibodies to hepatitis B core antigen (anti-HBc) and 48 (55.8 per cent) of the 86 patients tested for antibodies to hepatitis C (anti-HCV) were seropositive, respectively. Only one patient (1.1 per cent) of those tested for anti-HBc, was HBsAg positive, indicative of a carrier state; the same patient was also positive for HBeAg, a measure of high infectivity.
Gender differences for anti-HBc serology indicated that all 18 patients who were positive were male; none was female 
Injecting behaviour, anti-HBc and anti-HCV status
Eighty-seven patients, 85.3 per cent of the sample, had at some time in the past injected drugs, and of these, 53 (60.9 per cent) categorized as old injectors, had ceased injecting in the 30 days preceding interview; 34 (39.1 per cent) continued to inject.
Of the 34 patients categorized as current injectors, only six (17.6 per cent) and eight (23.5 per cent) reported lending or borrowing used injecting equipment in the preceding 30 days, respectively. The proportion of patients who reported direct sharing of injecting equipment was too small to permit further statistical analysis. However, indirect sharing at some time in the past involving cooking equipment and frontloading rituals achieved statistical signi®cance between seropositive and seronegative sub-groups (Table 1) . What is worrying, however, is that the mean number of times patients shared cooking equipment is higher for the seronegative groups, which suggests that other risk factors are important in acquiring the infection. As also shown in Table 1 , other variables signi®cantly associated with anti-HBc and anti-HCV seropositivity were the age of the patients at interview, the age at onset of opioid use and the duration of opioid use. Seropositive patients were signi®cantly older ( p 0:00001), had an earlier onset of opioid use ( p 0:001 for the anti-HBc group, and p 0:01 for the anti-HCV group, respectively) and had a signi®cantly longer duration of opioid use ( p 0:00001).
Sexual behaviour, anti-HBc and anti-HCV status
Of the 102 patients recruited into the study, 46 (45.1 per cent) were married or cohabiting; the others were single, separated or divorced. Ninety-®ve (93.1 per cent) were exclusively heterosexual; 67 (65.7 per cent) had a regular sexual partner; 21 (31.3 per cent) of the sexual partners were i.v. drug users (IVDU). Sexual risk behaviours for the whole sample were markedly low and the numbers in cells too small to permit close statistical scrutiny. Only one variable, vaginal intercourse without a condom, showed a signi®cant association with anti-HBc serological status (x 2 4:3506; p 0:03). None of the sexual risk behaviours compared for anti-HCV sub-groups achieved statistical signi®cance ( Table 2) . A higher proportion of seronegative patients had a regular sexual partner, but fewer used a condom.
Consent to HIV antibody testing
Excluding the 13 patients for whom blood specimens were not available, risk behaviours were compared for patients who gave informed consent for HIV antibody test and those who did not. There were no signi®cant differences on several variables between the two groups including age and sex (Table 3) . However, patients who consented to HIV antibody test were more likely to have regular drug-using partners (x 2 5:6167; p 0:017). It is interesting to note ( Table 3 ) that perceived risk of HIV infection was not a consideration for consent to antibody test, most of the patients having rated themselves to be at low risk.
Liver function and health service utilization
Twenty-three (25.7 per cent) of the 89 patients who provided blood specimens had serum aspartate aminotransferase concentrations above 40 IU/l and gamma-glutamyl transpeptidase activity in excess of 50 IU/l. Anti-HBc and anti-HCV serological status and liver function test results are shown in Table 4 . Though 86 (84.3 per cent) of the study sample said they had general practice consultations in the preceding 12 months, only 42 (41.2 per cent) had been referred to treatment by GPs. There was no signi®cant association between HBV and HCV serological status and general practice consultations. Only eight (7.8 per cent) of the 102 patients recruited into the study had previously received hepatitis B vaccination; 48 (47.1 per cent) had used accident and emergency departments in the preceding 12 months but only 7 (6.2 per cent) had been seen in a medical out-patient clinic.
Discussion
The results of our study con®rm many documented ®ndings about HIV, HBV and HCV but never previously investigated by face-to-face interviews and serological tests on blood specimens obtained directly from drug users in a treatment population in rural Britain. The prevalence of HIV in this study (1 in 27; 3.7 per cent) is higher than has been reported for hospital patients aged 16±49 years (1 in 167; 0.6 per cent) in the four Thames Regions. 16 Gruer et al. 6 reported an overall seroprevalence of HIV among drug injectors in Glasgow of 3. The proportion of patients borrowing or lending injecting equipment in our study sample was too small to permit rigorous statistical analysis. However, the signi®cant relationship demonstrated for sharing cooking equipment and drug use by frontloading rituals with anti-HBc and anti-HCV serological status lends support to the views expressed by Coutinho 17 that more attention should be paid to preventing indirect sharing, as this may be an important route of transmission. Our results show clearly that even when patients do not report a history of directly sharing injecting equipment, sharing of injecting accessories is equally relevant. Sexual risk behaviours in our sample were on the whole minimal; however, we observed a signi®cant relationship between anti-HBc serological status and vaginal intercourse without a condom. None of the sexual risk variables showed any association with the anti-HCV groups. Our study provides further evidence in support of previous ®ndings that hepatitis C is sexually transmitted much less commonly than either HIV or hepatitis B virus. 15 More importantly, we draw attention to the poor therapeutic options available to drug users in today's Britain. Hepatitis B vaccination 18 for injecting drug users has been recommended since 1985; however, the existence of a policy and the implementation of it are different matters. Farrell et al. 7 reported, in a questionnaire survey of statutory treatment facilities, that less than one-third offered hepatitis B vaccination. Of 126 consecutive patients attending a hepatology clinic in Cambridge, 8 84 of them i.v. drug users, only 7 per cent (9/ 126) had been offered hepatitis B vaccination, consistent with our own ®ndings.
Considering the prognosis for patients who have coinfection with HBV and HCV, Foster et al. 9 observed that the most striking feature of their retrospective audit of chronic hepatitis C positive patients seen in out-patient clinics over 12 months was their poor attendance. The poor uptake among drug users for hepatitis B vaccination and their poor compliance at follow-up, with or without HCV infection, suggest the need for a rethink about prevention and treatment strategies.
Less than one-third of our study sample consented to HIV antibody test, although the risk behaviours between the consenting and non-consenting groups were not markedly different. Why patients refuse to give consent for HIV antibody test remains a subject of continuing interest. 19 What indeed constitutes counselling for patients antibody positive for hepatitis C is unclear. Over 25 per cent of patients in our sample had serum aminotransferase and gamma-glutamyl transpeptidase concentrations above the upper limit of normal; though it is well documented that clinical and laboratory data are not useful predictors 20 of liver damage, the proportion of patients who have ever had liver biopsies remains unknown. However, concluding from the seven (6.2 per cent) known to have had contact with medical out-patient clinics, an exceedingly small number of patients would have had any access to liver biopsy.
Possible weaknesses of our study were the small sample size and important wider aspects of the research project that we did not cover in greater depth because of resource limitations. Funding was available only for 1 year and for one researcher; we conducted only baseline interviews and were unable to examine serological status in relation to changes in injecting and sexual risk behaviours, at follow-up. We tried to reduce sampling bias by ensuring that participants were unselected, and that consent to participate in the study did not imply consent to HIV antibody testing. Further research is necessary, including an unlinked anonymous survey to complement the voluntary testing for HIV antibodies, to obtain comparative prevalence ®gures and hence avoid errors of interpretation from potential participation bias.
Our knowledge of rural health needs is limited; 21 access to services is hampered by the widely dispersed population, and transport and mobility problems. Services for drug users require urgent appraisal, particularly for urban±rural differences, and more so for the public health implications of blood-borne viruses, apart from the patients' own health care needs. The provision of on-site phlebotomy facility for routine screening for blood-borne viral infections and offer of hepatitis B vaccination as an integral part of drug misuse treatment services would be a signi®cant step forward.
